Nonapeptide-1 vs AHK-Cu: comparing the evidence, cost, and who each one suits

I get some version of this question every time a reader compares two topical peptides on a supplier's site and picks based on price alone: is Nonapeptide-1 actually better than AHK-Cu, or are they just two names for the same idea?

Short answer: for the exact question the trial evidence answers, yes, Nonapeptide-1 vs AHK-Cu is not close. Nonapeptide-1 has a published randomized trial behind it. AHK-Cu does not. But "better evidence" and "better peptide for you" are two different questions, and they solve two entirely different problems, so the comparison only matters once you know which one you actually need.

What each one is actually built to do

Nonapeptide-1, sold under the name Melanostatine, works on melanocytes. It blocks alpha-MSH from binding to the MC1R receptor, which cuts the signal that ramps up tyrosinase, the enzyme that drives melanin production. In practice that means less pigment output at the source, which is why it shows up in melasma and dark-spot formulas.

AHK-Cu targets a different problem entirely. It sits in the copper-peptide family with GHK-Cu, but it is marketed almost exclusively for hair and scalp, not facial skin. The proposed mechanism is that the copper-peptide complex supports keratinocyte activity and follicle signaling. I use copper peptides in my own routine and I think the mechanism is plausible, but plausible mechanism and proven outcome are not the same claim, and AHK-Cu currently only has the first one.

The evidence gap, and why it is not close

Here is where the comparison gets uncomfortable for AHK-Cu fans. Nonapeptide-1's public evidence grade sits at moderate, with four total studies and one actual randomized controlled trial. That trial ran a proprietary combination formula containing Nonapeptide-1 against sunscreen alone for melasma maintenance, and it worked. The caveat, and it's a real one, is that the peptide was never isolated in that trial. You are looking at a formula's performance rather than the molecule's performance on its own. The mechanistic backbone behind that clinical result comes from separate work on the alpha-MSH and MC1R melanogenesis pathway, including follow-up research mapping the same receptor signaling.

AHK-Cu has zero published human trials. There is no thin evidence, no preliminary evidence, nothing published at all. Everything you read about AHK-Cu and hair density is inference from the broader copper-peptide literature or from user reports on forums. That does not make it worthless. It is a bet on mechanism and community experience rather than on a controlled trial.

Cost and what you're actually paying for

Both peptides are cheap relative to injectable compounds, since they're formulated into topical serums rather than sold as lyophilized vials for reconstitution. Where the trial gap actually costs you money is in confidence: with Nonapeptide-1 you can point to a real study and know roughly what outcome to expect over a defined timeline. With AHK-Cu you're paying for a plausible story and trusting the anecdote. If you are the kind of buyer who wants data before you spend, that difference should weigh into which one you try first. If you already have a working scalp routine and just want to add a low-risk topical, the absence of trials is less of a dealbreaker.

Side-effect load

Both compounds carry a benign safety record and neither has documented adverse effects specific to the isolated peptide, mostly because neither has been studied in isolation with a dedicated safety arm. Topical delivery keeps systemic exposure low for both, which is a meaningfully different risk profile than an injectable. If you want the fuller picture on how injectables and topicals differ on risk generally, I've written about that distinction in are peptides dangerous. For either of these two, the realistic risk is local irritation from the base formula rather than the peptide itself, and that shows up within the first couple weeks of use if it's going to show up at all.

Who each one actually suits

If your problem is melasma or stubborn hyperpigmentation and you want something with an actual trial behind it, Nonapeptide-1 is the more defensible pick, and the comparison with its topical cousin Argireline is worth a read if you're building a broader topical stack. If your concern is thinning hair or scalp density, AHK-Cu is the one built for that use case even though the data has not caught up to the marketing yet. Running one against the other for the same goal doesn't make sense since they were never competing for the same job in the first place. I see this mismatch constantly with clients who bought whichever peptide serum was cheaper without checking what it was actually formulated to treat.

Standard disclaimer:

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

Since these are topicals rather than the injectable peptide lines OHM has a wholesale relationship with, there's no dosing schedule to hand you here beyond what's printed on whatever serum you buy: apply as directed, usually once or twice daily, and give it at least eight to twelve weeks before deciding whether it's doing anything, since pigment and hair cycles both move slowly.

If you're weighing a broader topical or injectable stack and want to understand what pairs well with what, Nonapeptide-1 alongside Vialox is a related comparison worth reading, since it covers how topical peptides with different jobs sit together in the same routine.